[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from ...
弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是一种来源于成熟B细胞的侵袭性肿瘤,是最常见的NHL类型,中老年发病居多,男性略多于女性,病理类型复杂,其临床异质性大,同一种疾病表现不同的预后,那么分型及预后分层评分系统在临床...
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment Ruben A. L. de Groen Fleur A. de Groot Joost S. P. Vermaat ResearchOpen Access29 Apr 2025Blood Cancer Journal Volume: 15, P: 82 ...
DIFFUSE large B-cell lymphomasHIVNON-Hodgkin's lymphomaOVERALL survivalCANCER diagnosisRITUXIMABCombination antiretroviral therapy (ART) has improved outcomes for human immunodeficiency virus (HIV) associated non-Hodgkin lymphoma. This is an analysis of 127 patients with HIV with Burkitt lymphoma (HIV-BL...
弥漫大B细胞淋巴瘤（diffuse large B cell lymphoma, DLBCL）是一组大细胞、侵袭性的恶性淋巴瘤，是成人淋巴瘤中最常见的类型，约占所有淋巴瘤的40%。DLBCL在临床表现、组织形态和预后等多方面具有高度异质性。DLBCL最初被分为三个亚型：ABC（activated B cell-like）、GCB（germinal center B cell-like）和...
血清β2-微球蛋白水平可作为中国HIV相关弥漫大B细胞淋巴瘤患者生存预测的新型生物标志物 《Scientific Reports》:Serum β2-microglobulin level is associated with the survival of HIV-associated diffuse large B-cell lymphoma: a retrospective study from China...
[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Conso...
Cellular therapy increases survival in recurring B-cell lymphoma: Clinical trialhttps://medicalxpress.com/news/2024-02-cellular-therapy-survival-recurring-cell.html版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不...
大B细胞淋巴瘤（large B-cell lymphoma, LBCL）是非霍奇金淋巴瘤最常见的亚型，占非霍奇金淋巴瘤新发病例数的40% [1]。当前的LBCL一线治疗方案能使约60%的LBCL患者持久受益。但高危LBCL患者的预后较差[2]。报道显示，国际预后指数（International Prognostic Index, IPI）评分为3-5（高、中高风险）的LBCL...
[6] Shimin Hu,Zijun Y, Xu-Monette, et al.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program,...